Vaccines

A cautious, transparent response reveals a process committed to vaccine safety.

The ethics and safety of COVID-19 vaccines for pregnant people.

Josh Sharfstein answers a list of important questions about the COVID-19 vaccine.

Why are children not eligible for COVID-19 vaccines? Is it safe for unvaccinated children to go to school? Kawsar Talaat answers these questions and more.

Confronted with SARS-CoV-2 variants that could weaken mRNA vaccines? No problem.

True recovery from the pandemic will require mending broken systems and innovation to address generations-old inequity.

What you need to know about Johnson & Johnson’s nonreplicating viral vector vaccine for COVID-19.

Data collected in 23 countries in last two weeks of January reveal overall drop in COVID-19 vaccine acceptance, with increased acceptance in nine countries.

As variants spread, do they complicate COVID-19 testing? And will vaccinations change the accuracy of diagnostic and antibody tests?

Easy to manufacture and update, mRNA vaccines may be powerful tools against emerging variants and other infectious diseases.

While clinical trials are the gold standard to indicate if a vaccine’s benefits outweigh its risks, safety monitoring doesn’t stop there.

A new online calculator for estimating individual and community-level risk of dying from COVID-19 has been developed by researchers at the Johns Hopkins Bloomberg School of Public Health.

Pfizer’s encouraging early results from Phase 3 of its COVID-19 vaccine clinical trials mean we could see a vaccine by early 2021.

Faith leaders and community organizations play critical roles in enrolling Black and Latinx trial participants.

Researchers at the Bloomberg School and School of Medicine have been jointly awarded a major grant from the National Cancer Institute to set up a center for research on the human serological immune response to COVID-19.